These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 28320090)

  • 1. Treatment with anti-programmed cell death 1 (PD-1) antibody restored postoperative CD8+ T cell dysfunction by surgical stress.
    Sun Z; Mao A; Wang Y; Zhao Y; Chen J; Xu P; Miao C
    Biomed Pharmacother; 2017 May; 89():1235-1241. PubMed ID: 28320090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.
    Shindo Y; Unsinger J; Burnham CA; Green JM; Hotchkiss RS
    Shock; 2015 Apr; 43(4):334-43. PubMed ID: 25565644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.
    Golden-Mason L; Palmer B; Klarquist J; Mengshol JA; Castelblanco N; Rosen HR
    J Virol; 2007 Sep; 81(17):9249-58. PubMed ID: 17567698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
    Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
    Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer.
    Shen Y; Teng Y; Lv Y; Zhao Y; Qiu Y; Chen W; Wang L; Wang Y; Mao F; Cheng P; Ma D; Zhuang Y; Zou Q; Peng L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy.
    Li C; Li W; Xiao J; Jiao S; Teng F; Xue S; Zhang C; Sheng C; Leng Q; Rudd CE; Wei B; Wang H
    EMBO Mol Med; 2015 Jun; 7(6):754-69. PubMed ID: 25851535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.
    Li Z; Liu X; Guo R; Wang P
    Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of programmed death receptor-1 signaling restores expression of mostly proinflammatory cytokines in anergic cytomegalovirus-specific T cells.
    Dirks J; Egli A; Sester U; Sester M; Hirsch HH
    Transpl Infect Dis; 2013 Feb; 15(1):79-89. PubMed ID: 23176118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy.
    Schroder PM; Khattar M; Baum CE; Miyahara Y; Chen W; Vyas R; Muralidharan S; Mierzejewska B; Stepkowski SM
    Diabetologia; 2015 Jun; 58(6):1309-18. PubMed ID: 25794782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
    Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
    Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
    Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
    J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 and Tim-3 pathways are associated with regulatory CD8+ T-cell function in decidua and maintenance of normal pregnancy.
    Wang SC; Li YH; Piao HL; Hong XW; Zhang D; Xu YY; Tao Y; Wang Y; Yuan MM; Li DJ; Du MR
    Cell Death Dis; 2015 May; 6(5):e1738. PubMed ID: 25950468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD-1 Antibody Administration following Hip Fracture Surgery Reverses Immune Dysfunction and Decreases Susceptibility to Infection.
    Zhang H; Chen C; He J; Zhang J; Liu Z; Sun T
    Mediators Inflamm; 2019; 2019():8492090. PubMed ID: 31073275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.
    Sun Z; Fourcade J; Pagliano O; Chauvin JM; Sander C; Kirkwood JM; Zarour HM
    Cancer Res; 2015 Apr; 75(8):1635-44. PubMed ID: 25720800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis.
    Concepcion AR; Salas JT; Sáez E; Sarvide S; Ferrer A; Portu A; Uriarte I; Hervás-Stubbs S; Oude Elferink RP; Prieto J; Medina JF
    Oncotarget; 2015 Oct; 6(30):28588-606. PubMed ID: 26396175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection.
    Xu A; Wang R; Freywald A; Stewart K; Tikoo S; Xu J; Zheng C; Xiang J
    Biochem Biophys Res Commun; 2017 Mar; 484(3):662-667. PubMed ID: 28153727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.
    Kobold S; Grassmann S; Chaloupka M; Lampert C; Wenk S; Kraus F; Rapp M; Düwell P; Zeng Y; Schmollinger JC; Schnurr M; Endres S; Rothenfußer S
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26105028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.